James Thrasher

5.2k total citations · 1 hit paper
20 papers, 623 citations indexed

About

James Thrasher is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, James Thrasher has authored 20 papers receiving a total of 623 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Surgery and 7 papers in Molecular Biology. Recurrent topics in James Thrasher's work include Pancreatic function and diabetes (10 papers), Diabetes Treatment and Management (9 papers) and Diabetes Management and Research (9 papers). James Thrasher is often cited by papers focused on Pancreatic function and diabetes (10 papers), Diabetes Treatment and Management (9 papers) and Diabetes Management and Research (9 papers). James Thrasher collaborates with scholars based in United States, Germany and United Kingdom. James Thrasher's co-authors include Bernhard Ludvik, Desirée Thielke, Bernard Zinman, Athena Philis‐Tsimikas, Vincent Woo, Vaishali Bhosekar, Ingrid Holst, Robert S. Busch, George Dunaway and M D Cooper and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Biochemical and Biophysical Research Communications.

In The Last Decade

James Thrasher

20 papers receiving 596 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

2019 267 citations Bernard Zinman, Vaishali Bhosekar et al. The Lancet Diabetes & Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Thrasher United States	10	469	301	181	112	70	20	623
Huan Xue China	9	221 0.5×	184 0.6×	87 0.5×	88 0.8×	64 0.9×	18	460
Martina Kinner Germany	9	271 0.6×	225 0.7×	213 1.2×	35 0.3×	75 1.1×	9	668
Chikage Sato Japan	8	290 0.6×	169 0.6×	146 0.8×	50 0.4×	62 0.9×	9	551
Simon Gross Australia	7	293 0.6×	157 0.5×	136 0.8×	54 0.5×	24 0.3×	8	512
Xiangjin Xu China	14	245 0.5×	162 0.5×	103 0.6×	47 0.4×	72 1.0×	32	529
Amanda Garza United States	13	274 0.6×	246 0.8×	115 0.6×	39 0.3×	55 0.8×	28	588
H.-U. Häring Germany	13	182 0.4×	154 0.5×	101 0.6×	52 0.5×	110 1.6×	29	493
Philipp Welschof Germany	7	429 0.9×	226 0.8×	228 1.3×	68 0.6×	112 1.6×	9	657
Elizabeth Sanchez‐Rangel United States	6	186 0.4×	261 0.9×	114 0.6×	23 0.2×	111 1.6×	8	527
Aya Shiraki Japan	8	215 0.5×	168 0.6×	99 0.5×	38 0.3×	84 1.2×	16	513

Countries citing papers authored by James Thrasher

Since Specialization

Citations

This map shows the geographic impact of James Thrasher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Thrasher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Thrasher more than expected).

Fields of papers citing papers by James Thrasher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Thrasher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Thrasher. The network helps show where James Thrasher may publish in the future.

Co-authorship network of co-authors of James Thrasher

This figure shows the co-authorship network connecting the top 25 collaborators of James Thrasher. A scholar is included among the top collaborators of James Thrasher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Thrasher. James Thrasher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Philis‐Tsimikas, Athena, Richard M. Bergenstal, Timothy S. Bailey, et al.. (2025). Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. The Lancet. 405(10497). 2279–2289. 4 indexed citations

Bhargava, Anuj, Richard M. Bergenstal, Mark Warren, et al.. (2025). Safety and Effectiveness of MiniMed ^TM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes. Diabetes Technology & Therapeutics. 27(5). 366–375. 3 indexed citations

Thrasher, James, et al.. (2024). Chapter 4: Summary and a Patient Perspective on Living with Heart Failure. The American Journal of Medicine. 137(2). S35–S42. 1 indexed citations

Thrasher, James, Arcelia Arrieta, Fang Niu, et al.. (2024). Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States. Diabetes Technology & Therapeutics. 26(3_suppl). 24–31. 13 indexed citations

Thrasher, James, Sarit Polsky, Irene Nowotny, et al.. (2019). Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial. Diabetes Technology & Therapeutics. 22(9). 666–673. 7 indexed citations

Zinman, Bernard, Vaishali Bhosekar, Robert S. Busch, et al.. (2019). Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 7(5). 356–367. 267 indexed citations breakdown →

Thrasher, James, et al.. (2018). Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. Journal of Diabetes Science and Technology. 12(3). 680–686. 15 indexed citations

Thrasher, James. (2017). Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. The American Journal of Cardiology. 120(1). S4–S16. 80 indexed citations

Thrasher, James. (2017). Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. The American Journal of Medicine. 130(6). S4–S17. 84 indexed citations

10.

Weiss, Ram, Satish K. Garg, Richard M. Bergenstal, et al.. (2015). Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery. Journal of Diabetes Science and Technology. 9(5). 1016–1020. 9 indexed citations

11.

Thrasher, James, David S. Kountz, Susanne Crowe, Hans‐Juergen Woerle, & Maximilian von Eynatten. (2015). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials. Postgraduate Medicine. 127(5). 419–428. 3 indexed citations

12.

Thrasher, James, Anuj Bhargava, Tina M. Rees, et al.. (2014). Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients With Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart. Endocrine Practice. 21(3). 247–257. 4 indexed citations

13.

Thrasher, James, et al.. (2013). Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-Month, Randomized, Double-Blind, Placebo-Controlled Study. Endocrine Practice. 20(5). 412–420. 20 indexed citations

14.

Thrasher, James, et al.. (2012). Black/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin. Expert Opinion on Pharmacotherapy. 13(17). 2443–2452. 9 indexed citations

15.

Thrasher, James, et al.. (1996). Syncope and aortic valve stenosis: clues to diagnosis and pathophysiology.. PubMed. 93(4). 191–3. 1 indexed citations

16.

Thrasher, James, M D Cooper, & George Dunaway. (1981). Developmental changes in heart and muscle phosphofructokinase isozymes.. Journal of Biological Chemistry. 256(15). 7844–7848. 31 indexed citations

17.

Dunaway, George, et al.. (1981). Phosphofructokinase isozymes of Morris hepatomas. Archives of Biochemistry and Biophysics. 212(1). 1–8. 11 indexed citations

18.

Dunaway, George, et al.. (1979). Regulation of rat liver phosphofructokinase levels in Morris hepatomas. Biochemical and Biophysical Research Communications. 88(3). 882–886. 4 indexed citations

19.

Dunaway, George, et al.. (1978). Distribution of hepatic phosphofructokinase isozymes in parenchymal and sinusoidal cells. Biochemical and Biophysical Research Communications. 80(1). 71–74. 20 indexed citations

20.

Dunaway, George, et al.. (1978). Turnover of hepatic phosphofructokinase in normal and diabetic rats. Role of insulin and peptide stabilizing factor.. Journal of Biological Chemistry. 253(20). 7460–7463. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact